UK Markets closed

Zymeworks Inc. (ZYME)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
6.30-0.02 (-0.32%)
At close: 04:00PM EDT

Zymeworks Inc.

114 East 4th Avenue
Suite 800
Vancouver, BC V5T 1G4
Canada

https://www.zymeworks.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees455

Key executives

NameTitlePayExercisedYear born
Mr. Neil A. Klompas C.A., CPA, CA, CPAChief Operating Officer589.86kN/A1972
Dr. Ali Tehrani Ph.D.Advisor877.66kN/A1972
Mr. Kenneth H. Galbraith C.A.Pres, CEO & ChairmanN/AN/A1963
Mr. Chris Astle Ph.D.Sr. VP & CFON/AN/AN/A
Jack W. SpinksMang. of Investor RelationsN/AN/AN/A
Mr. Daniel Dex J.D., Ph.D.VP of Legal & Corp. Sec.N/AN/AN/A
Mr. Mark HollywoodSr. VP of Technical & Manufacturing OperationsN/AN/A1970
Dr. Bruce Hart Ph.D.Sr. VP of RegulatoryN/AN/AN/A
Dr. Neil Josephson M.D.Chief Medical OfficerN/AN/AN/A
Dr. David Poon Ph.D.VP of Bus. Devel. and Alliance ManagementN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Corporate governance

Zymeworks Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.